Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (204)	3/29/2002 11:13:22 AM
From: tuck	Read Replies (1) of 469

Links backing my prior post . . . Here's one concerning the types of Gaucher's and which ones see neurological problems: gaucher.org.uk I have not seen mention of neurological problems in connection with Cerezyme, so I'm not in complete agreement with Rick's contention on the T/FIF thread that some safety issues can be tolerated in Vevesca. Adverse reactions to Cerezyme are pretty minor & uncommon. Here's the Cerezyme package insert: gaucherregistry.com Wilder, thanks for the link to the webcast. I should be able to get to that later today. Whether or not I can reconcile these issues, I'll post my final thoughts. Interesting that OGSI is composing an anecdotal database of neurological effects of the disease. It's not like this disease hasn't been studied for a century; are they implying these effects went unnoticed by the medical community until recently? How noticeable are the effects in question? Hence my interest in the types of the disease the patients have that OGSI has been dealing with. I agree with Ralf that Vevesca failure would not hurt OGSI as much as a lead compound failure would hurt another biotech; it seems failure has been priced in. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next